drugset / Trial / NCT05961007
Evaluation of IBI302 Injection in nAMD or DME
RandomizedSequentialDouble-blindTreatment
Summary
The purpose of this study is to determine the efficacy and safety of intravitreal IBI302 in the treatment of subjects with neovascular age-related macular degeneration (only in Phase I) or diabetic macular edema.
Timeline
- Start
- 2021-11-18
- Primary completion
- 2023-10-31
- Completion
- 2024-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aflibercept | Protein / enzyme biologic | — | Intravitreal |
| Subject | IBI302 | Unknown | — | Intravitreal |